{
  "abstract": null,
  "abstract_shown": false,
  "affiliations": [
    "1Honor Health, Scottsdale, AZ, USA",
    "25 Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA",
    "University of Texas Southwestern Medical Center, Dallas, TX, USA",
    "6Northwestern University, Chicago, IL, USA",
    "Hackensack University Medical Center Center, Hackensack, New Jersey, USA",
    "1 Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, New York, USA",
    "Werewolf Therapeutics Inc., Watertown, MA, USA",
    "Hematology, New York Medical College, Valhalla, New York, USA",
    "10Werewolf Therapeutics, Reading, MA, USA",
    "NEXT Oncology, San Antonio, TX, USA",
    "Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA",
    "H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA",
    "Cogitars GmbH, Heidelberg, Baden-Württemberg, Germany",
    "Winship Cancer Institute of Emory University, Atlanta, GA, USA",
    "Texas Oncology-Houston Medical Center Next Oncology, Houston, TX, USA"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 18,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Justin Moser"
    },
    {
      "affs": [
        1
      ],
      "name": "Igor Puzanov"
    },
    {
      "affs": [
        2
      ],
      "name": "Hans Hammers"
    },
    {
      "affs": [
        3
      ],
      "name": "Sunandana Chandra"
    },
    {
      "affs": [
        4
      ],
      "name": "Martin Gutierrez"
    },
    {
      "affs": [
        5
      ],
      "name": "Rohan Maniar"
    },
    {
      "affs": [
        6
      ],
      "name": "Kristin Morris"
    },
    {
      "affs": [
        7
      ],
      "name": "Amir Steinberg"
    },
    {
      "affs": [
        8
      ],
      "name": "Saero Park"
    },
    {
      "affs": [
        9
      ],
      "name": "Ismael Rodriguez Rivera"
    },
    {
      "affs": [
        10
      ],
      "name": "Brendan D Curti"
    },
    {
      "affs": [
        11
      ],
      "name": "Ahmad A Tarhini"
    },
    {
      "affs": [
        6
      ],
      "name": "Kulandayan K Subramanian"
    },
    {
      "affs": [
        12
      ],
      "name": "Matt Chapman-Rounds"
    },
    {
      "affs": [
        6
      ],
      "name": "Randi E Isaacs"
    },
    {
      "affs": [
        6
      ],
      "name": "Sameer S Chopra"
    },
    {
      "affs": [
        13
      ],
      "name": "Mehmet A Bilen"
    },
    {
      "affs": [
        14
      ],
      "name": "Jennifer M Segar"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/0f6qqn6cw5ntb.bib",
  "cited_by": 0,
  "doi": "10.1136/jitc-2026-sitc2026.1189",
  "fulltext_url": null,
  "id": "0f6qqn6cw5ntb",
  "issns": [
    "2051-1426"
  ],
  "landing_url": "https://doi.org/10.1136/jitc-2026-sitc2026.1189",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "RC254-282"
    ],
    [
      "openalex",
      "2730|Cancer Immunotherapy and Biomarkers"
    ]
  ],
  "openalex": "W7225428506",
  "pdf_url": "https://jitc.bmj.com/content/14/Suppl_3/A1405.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-08",
  "publisher": "BMJ Publishing Group",
  "ris": "https://research.draconitic.com/paper/0f6qqn6cw5ntb.ris",
  "sources": [
    {
      "first_seen": "2026-11-08T14:20:55Z",
      "native_id": "01c60c2afa03455885416eb24835f51f",
      "source": "doaj",
      "url": "https://doi.org/10.1136/jitc-2026-sitc2026.1189"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Cancer Immunotherapy and Biomarkers",
      "subfield": "oncology"
    }
  ],
  "title": "1189 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with relapsed/refractory, advanced/metastatic, immunotherapy-sensitive solid tumors",
  "title_text": "1189 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with relapsed/refractory, advanced/metastatic, immunotherapy-sensitive solid tumors",
  "type": "peer-reviewed",
  "updated_at": "2026-11-08T14:20:55Z",
  "url": "https://research.draconitic.com/paper/0f6qqn6cw5ntb",
  "venue": "Journal for ImmunoTherapy of Cancer",
  "versions": []
}